1887

Abstract

It has been well established that immunological escape mutations within the hepatitis C virus genotype (gt) 1a non-structural (NS) 3/4A protease are partly prevented by a reduction in viral protease fitness. Surprisingly little is known about whether similar mutations affect proteases from other genotypes. In the present study, we assessed both the HLA-A2-restricted CTL response and gt3a NS3/4A protease fitness. Similar to gt1, the 1073–1081 epitope was immunodominant within the gt3a-specific HLA-A2-restricted CTL response, despite sequence similarity of only 56 % between the gt1a and gt3a genes. However, unlike the gt1a NS3/4A protease, all residues within the gt3a 1073–1081 epitope could be replaced sequentially by alanine while retaining protease activity, at least in part.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.043745-0
2012-08-01
2020-07-11
Loading full text...

Full text loading...

/deliver/fulltext/jgv/93/8/1680.html?itemId=/content/journal/jgv/10.1099/vir.0.043745-0&mimeType=html&fmt=ahah

References

  1. Abramoff M. D., Magalhaes P. J., Ram S. J.. 2004; Image processing with ImageJ. Biophotonics Int11:36–42
    [Google Scholar]
  2. Bartenschlager R.. 2002; Hepatitis C virus replicons: potential role for drug development. Nat Rev Drug Discov1:911–916 [CrossRef][PubMed]
    [Google Scholar]
  3. Binder J., Tetangco S., Weinshank M., Maegley K., Lingardo L., Diehl W., Love R., Patick A. K., Smith G. J. III. 2011; Development of hepatitis C virus chimeric replicons for identifying broad spectrum NS3 protease inhibitors. Antiviral Res91:102–111 [CrossRef][PubMed]
    [Google Scholar]
  4. Bowen D. G., Walker C. M.. 2005; Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature436:946–952 [CrossRef][PubMed]
    [Google Scholar]
  5. Brenndörfer E. D., Brass A., Söderholm J., Frelin L., Aleman S., Bode J. G., Sällberg M.. 2012; Hepatitis C virus non-structural 3/4A protein interferes with intrahepatic interferon-γ production. Gut61:589–596 [CrossRef][PubMed]
    [Google Scholar]
  6. Duong F. H., Filipowicz M., Tripodi M., La Monica N., Heim M. H.. 2004; Hepatitis C virus inhibits interferon signaling through up-regulation of protein phosphatase 2A. Gastroenterology126:263–277 [CrossRef][PubMed]
    [Google Scholar]
  7. Fitzmaurice K., Petrovic D., Ramamurthy N., Simmons R., Merani S., Gaudieri S., Sims S., Dempsey E., Freitas E..other authors 2011; Molecular footprints reveal the impact of the protective HLA-A*03 allele in hepatitis C virus infection. Gut60:1563–1571 [CrossRef][PubMed]
    [Google Scholar]
  8. Foy E., Li K., Wang C., Sumpter R. Jr, Ikeda M., Lemon S. M., Gale M. Jr. 2003; Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease. Science300:1145–1148 [CrossRef][PubMed]
    [Google Scholar]
  9. Frelin L., Alheim M., Chen A., Söderholm J., Rozell B., Barnfield C., Liljeström P., Sällberg M.. 2003; Low dose and gene gun immunization with a hepatitis C virus nonstructural (NS) 3 DNA-based vaccine containing NS4A inhibit NS3/4A-expressing tumors in vivo. Gene Ther10:686–699 [CrossRef][PubMed]
    [Google Scholar]
  10. Frelin L., Ahlén G., Alheim M., Weiland O., Barnfield C., Liljeström P., Sällberg M.. 2004; Codon optimization and mRNA amplification effectively enhances the immunogenicity of the hepatitis C virus nonstructural 3/4A gene. Gene Ther11:522–533 [CrossRef][PubMed]
    [Google Scholar]
  11. Frelin L., Brenndörfer E. D., Ahlén G., Weiland M., Hultgren C., Alheim M., Glaumann H., Rozell B., Milich D. R..other authors 2006; The hepatitis C virus and immune evasion: non-structural 3/4A transgenic mice are resistant to lethal tumour necrosis factor alpha mediated liver disease. Gut55:1475–1483 [CrossRef][PubMed]
    [Google Scholar]
  12. Fytili P., Dalekos G. N., Schlaphoff V., Suneetha P. V., Sarrazin C., Zauner W., Zachou K., Berg T., Manns M. P..other authors 2008; Cross-genotype-reactivity of the immunodominant HCV CD8 T-cell epitope NS3-1073. Vaccine26:3818–3826 [CrossRef][PubMed]
    [Google Scholar]
  13. Gale M. Jr, Foy E. M.. 2005; Evasion of intracellular host defence by hepatitis C virus. Nature436:939–945 [CrossRef][PubMed]
    [Google Scholar]
  14. Giugliano S., Oezkan F., Bedrejowski M., Kudla M., Reiser M., Viazov S., Scherbaum N., Roggendorf M., Timm J.. 2009; Degree of cross-genotype reactivity of hepatitis C virus-specific CD8+ T cells directed against NS3. Hepatology50:707–716 [CrossRef][PubMed]
    [Google Scholar]
  15. Gottwein J. M., Scheel T. K., Jensen T. B., Ghanem L., Bukh J.. 2011; Differential efficacy of protease inhibitors against HCV genotypes 2a, 3a, 5a, and 6a NS3/4A protease recombinant viruses. Gastroenterology141:1067–1079 [CrossRef][PubMed]
    [Google Scholar]
  16. Li K., Foy E., Ferreon J. C., Nakamura M., Ferreon A. C., Ikeda M., Ray S. C., Gale M. Jr, Lemon S. M.. 2005; Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF. Proc Natl Acad Sci U S A102:2992–2997 [CrossRef][PubMed]
    [Google Scholar]
  17. Ljunggren H. G., Oudshoorn-Snoek M., Masucci M. G., Ploegh H. L.. 1990; High-resolution one-dimensional isoelectric focusing of mouse MHC class I antigens. Identification of natural and experimentally induced class I antigens. Immunogenetics32:440–450 [CrossRef][PubMed]
    [Google Scholar]
  18. Meylan E., Curran J., Hofmann K., Moradpour D., Binder M., Bartenschlager R., Tschopp J.. 2005; Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. Nature437:1167–1172 [CrossRef][PubMed]
    [Google Scholar]
  19. Munir S., Saleem S., Idrees M., Tariq A., Butt S., Rauff B., Hussain A., Badar S., Naudhani M..other authors 2010; Hepatitis C treatment: current and future perspectives. Virol J7:296 [CrossRef][PubMed]
    [Google Scholar]
  20. Poordad F., McCone J. Jr, Bacon B. R., Bruno S., Manns M. P., Sulkowski M. S., Jacobson I. M., Reddy K. R., Goodman Z. D..other authors 2011; Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med364:1195–1206 [CrossRef][PubMed]
    [Google Scholar]
  21. Rauch A., James I., Pfafferott K., Nolan D., Klenerman P., Cheng W., Mollison L., McCaughan G., Shackel N..other authors 2009; Divergent adaptation of hepatitis C virus genotypes 1 and 3 to human leukocyte antigen-restricted immune pressure. Hepatology50:1017–1029 [CrossRef][PubMed]
    [Google Scholar]
  22. Sällberg M., Rudén U., Magnius L. O., Norrby E., Wahren B.. 1991; Rapid “tea-bag” peptide synthesis using 9-fluorenylmethoxycarbonyl (Fmoc) protected amino acids applied for antigenic mapping of viral proteins. Immunol Lett30:59–68 [CrossRef][PubMed]
    [Google Scholar]
  23. Salloum S., Oniangue-Ndza C., Neumann-Haefelin C., Hudson L., Giugliano S., aus dem Siepen M., Nattermann J., Spengler U., Lauer G. M..other authors 2008; Escape from HLA-B*08-restricted CD8 T cells by hepatitis C virus is associated with fitness costs. J Virol82:11803–11812 [CrossRef][PubMed]
    [Google Scholar]
  24. Seth R. B., Sun L., Ea C. K., Chen Z. J.. 2005; Identification and characterization of MAVS, a mitochondrial antiviral signaling protein that activates NF-kappaB and IRF 3. Cell122:669–682 [CrossRef][PubMed]
    [Google Scholar]
  25. Simmonds P., Bukh J., Combet C., Deléage G., Enomoto N., Feinstone S., Halfon P., Inchauspé G., Kuiken C..other authors 2005; Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology42:962–973 [CrossRef][PubMed]
    [Google Scholar]
  26. Söderholm J., Sallberg M.. 2006; A complete mutational fitness map of the hepatitis C virus nonstructural 3 protease: relation to recognition by cytotoxic T lymphocytes. J Infect Dis194:1724–1728 [CrossRef][PubMed]
    [Google Scholar]
  27. Söderholm J., Ahlén G., Kaul A., Frelin L., Alheim M., Barnfield C., Liljeström P., Weiland O., Milich D. R..other authors 2006; Relation between viral fitness and immune escape within the hepatitis C virus protease. Gut55:266–274 [CrossRef][PubMed]
    [Google Scholar]
  28. WHO 1999; Global surveillance and control of hepatitis C. J Viral Hepat6:35–47 [CrossRef][PubMed]
    [Google Scholar]
  29. Zeuzem S., Andreone P., Pol S., Lawitz E., Diago M., Roberts S., Focaccia R., Younossi Z., Foster G. R..other authors 2011; Telaprevir for retreatment of HCV infection. N Engl J Med364:2417–2428 [CrossRef][PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.043745-0
Loading
/content/journal/jgv/10.1099/vir.0.043745-0
Loading

Data & Media loading...

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error